Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02536469 | HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | PHASE1 | COMPLETED | 15 | — | — | Aug 1, 2015 | Nov 1, 2016 | Feb 3, 2017 | 1 | United States |
The primary endpoint of this study is the proportion of patients who experience DLTs. The MTD (Maximum Tolerated Dose) will be determined based on the dose escalation cohorts. The evaluation period for DLTs will be 28 days following the first dose of HuMax-IL8
| Arm | Type | Description |
|---|---|---|
| HuMax-IL8 | EXPERIMENTAL | HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle |
| Name | Type | Description |
|---|---|---|
| HuMax-IL8 | DRUG | HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle |
Inclusion Criteria: * Subjects must have metastatic or unresectable locally advanced malignant solid tumor. * Patients may have measurable or non-measurable but evaluable disease. * Patients with surgically resected metastatic disease at high risk of relapse are also eligible. * Patients must have ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |